Pfizer Inc. has objected to two aspects of a proposed order to pay for discovery undertaken for the common benefit of plaintiffs who allege birth defects were caused by the use of the antidepressant Effexor.
While the drug maker and the plaintiffs lawyers agree on many aspects of the common-benefit fund in the Effexor multidistrict litigation, they disagree on two aspects, which Pfizer says would “adversely impact defendants’ ability to maintain the confidentiality of any settlement agreements that may be reached in this litigation,” according to a defense court filing.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
